OTCPK:ALBBY (China)
Â
ADR
$
12.85
(0%)
12:08 AM EST
What is a stock summary page? Click here for an overview.
Business Description
Alibaba Health Information Technology Ltd
ISIN : US01609Y1082
Share Class Description:
ALBBY: ADRCompare
Compare
Traded in other countries / regions
00241.Hong KongTWY.GermanyALBHF.USA241.Mexico IPO Date
2017-06-13Description
Alibaba Health is of one of China's leading e-commerce platform specializing in healthcare-related products, including prescription drugs, OTC drugs, traditional Chinese medicine, health foods, and so on. The company operates both a third-party B2C service, or 3P, and its own direct-to-consumer business, or 1P, with its own inventory, which can both be accessed by Alibaba's Tmall app and Alipay. The company also provides online consultation services in a separate app called Yilu or "Dr. Deer", although its e-commerce businesses remain its core competency in the long-term. E-commerce accounted for 97% of revenue in fiscal year 2022. We estimate that AliHealth holds about 45% of market share in the industry in terms of GMV. AliHealth is 63.74% owned by its parent company, Alibaba Group.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 113.65 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-EBITDA | 0.05 | |||||
Interest Coverage | 242.58 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 11.3 | |||||
Beneish M-Score | -2.03 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.5 | |||||
3-Year EBITDA Growth Rate | 24.4 | |||||
3-Year EPS without NRI Growth Rate | 44.2 | |||||
3-Year FCF Growth Rate | -3.1 | |||||
3-Year Book Growth Rate | -8.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 42.85 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.78 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 31.45 | |||||
9-Day RSI | 40.83 | |||||
14-Day RSI | 47.08 | |||||
3-1 Month Momentum % | 52.23 | |||||
6-1 Month Momentum % | 31.82 | |||||
12-1 Month Momentum % | 51.89 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.45 | |||||
Quick Ratio | 2.11 | |||||
Cash Ratio | 1.59 | |||||
Days Inventory | 26.42 | |||||
Days Sales Outstanding | 9.51 | |||||
Days Payable | 54.62 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.1 | |||||
Shareholder Yield % | 0.15 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 23.16 | |||||
Operating Margin % | 4.27 | |||||
Net Margin % | 4.26 | |||||
FCF Margin % | 2.56 | |||||
ROE % | 7.95 | |||||
ROA % | 5.94 | |||||
ROIC % | 15.53 | |||||
3-Year ROIIC % | 21.6 | |||||
ROC (Joel Greenblatt) % | 1296.52 | |||||
ROCE % | 8.39 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 58.94 | |||||
Forward PE Ratio | 31.27 | |||||
PE Ratio without NRI | 62.38 | |||||
Price-to-Owner-Earnings | 112.32 | |||||
PS Ratio | 2.5 | |||||
PB Ratio | 4.85 | |||||
Price-to-Tangible-Book | 5.24 | |||||
Price-to-Free-Cash-Flow | 101.08 | |||||
Price-to-Operating-Cash-Flow | 99.1 | |||||
EV-to-EBIT | 51.29 | |||||
EV-to-Forward-EBIT | 49.22 | |||||
EV-to-EBITDA | 49.19 | |||||
EV-to-Forward-EBITDA | 48.02 | |||||
EV-to-Revenue | 2.33 | |||||
EV-to-Forward-Revenue | 2.02 | |||||
EV-to-FCF | 99.17 | |||||
Price-to-GF-Value | 0.8 | |||||
Price-to-Projected-FCF | 3.35 | |||||
Price-to-Median-PS-Value | 0.1 | |||||
Price-to-Graham-Number | 3.86 | |||||
Price-to-Net-Current-Asset-Value | 10.8 | |||||
Price-to-Net-Cash | 26.77 | |||||
Earnings Yield (Greenblatt) % | 1.95 | |||||
FCF Yield % | 0.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ALBBY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alibaba Health Information Technology Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 3,971.039 | ||
EPS (TTM) ($) | 0.218 | ||
Beta | 0.92 | ||
3-Year Sharpe Ratio | 0.24 | ||
3-Year Sortino Ratio | 0.5 | ||
Volatility % | 82.1 | ||
14-Day RSI | 47.08 | ||
14-Day ATR ($) | 0.419369 | ||
20-Day SMA ($) | 13.4175 | ||
12-1 Month Momentum % | 51.89 | ||
52-Week Range ($) | 6.88 - 16.5 | ||
Shares Outstanding (Mil) | 804.59 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Alibaba Health Information Technology Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Alibaba Health Information Technology Ltd Stock Events
Event | Date | Price ($) | ||
---|---|---|---|---|
No Event Data |
Alibaba Health Information Technology Ltd Frequently Asked Questions
What is Alibaba Health Information Technology Ltd(ALBBY)'s stock price today?
The current price of ALBBY is $12.85. The 52 week high of ALBBY is $16.50 and 52 week low is $6.88.
When is next earnings date of Alibaba Health Information Technology Ltd(ALBBY)?
The next earnings date of Alibaba Health Information Technology Ltd(ALBBY) is 2025-05-23 Est..
Does Alibaba Health Information Technology Ltd(ALBBY) pay dividends? If so, how much?
Alibaba Health Information Technology Ltd(ALBBY) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |